SNCA and Parkinson disease: Although NAD+ administration has shown potential in decreasing neuroinflammation and preserving mitochondrial function, an alternative strategy for addressing α-synuclein aggregation, a significant factor in PD, is the utilization of carbenoxolone (Cbx).